期刊
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 98, 期 12, 页码 4798-4807出版社
ENDOCRINE SOC
DOI: 10.1210/jc.2013-2674
关键词
-
资金
- Academy of Finland
- Sigrid Juselius Foundation
- Finnish Medical Foundation
- National Clinical Graduate School
- Research Foundation of Obstetrics and Gynecology
- Oulu University Scholarship Foundation
- North Ostrobothnia Regional fund of the Finnish Cultural Foundation
- Tyyni Tani Foundation of the University of Oulu
- Finnish-Norwegian Medical Foundation
Context: Statins have been shown to improve hyperandrogenism in women with polycystic ovary syndrome (PCOS). However, their use has also been associated with impairment of glucose metabolism and an increased risk of type 2 diabetes mellitus. Because women with PCOS are prone to disturbances in glucose metabolism, statin therapy could also have negative effects. Objective: Our objective was to explore the effects of atorvastatin therapy on hormonal and metabolic parameters in women with PCOS. Design and Setting: We conducted a randomized, double-blind, placebo-controlled 6-month follow-up study conducted at Oulu University Hospital, Finland. Patients: Women with PCOS (Rotterdam criteria) were treated with atorvastatin (20 mg/d, n = 15) or placebo (n = 13) for 6 months. Interventions: Fasting serum samples were collected at baseline and at 3 and 6 months. Oral and iv glucose tolerance tests were performed at 0 and 6 months. Main Outcome Measures: Androgen secretion and glucose metabolism were measured. Results: Fasting levels and area under the curve of insulin increased significantly and insulin sensitivity (insulinogenic and Matsuda indexes) decreased during 6 months of atorvastatin therapy. Serum levels of dehydroepiandrosterone sulfate decreased in the atorvastatin group, whereas no change was observed in serum testosterone levels. Levels of C-reactive protein, total and low-density lipoprotein-cholesterol, and triglycerides decreased significantly during statin therapy. Conclusions: Atorvastatin therapy improves chronic inflammation and lipid profile, but it impairs insulin sensitivity in women with PCOS. Because women with PCOS have an increased risk of developing type 2 diabetes mellitus, the results suggest that statin therapy should be initiated on the basis of generally accepted criteria and individual risk assessment of cardiovascular disease, and not only because of PCOS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据